

REMARKS

The amendments to the specification submitted herein are to correct an obvious typographical error at page 4, line 6, and to insert a sequence identifier at page 11, line 5.

Also submitted herewith are a sequence listing in computer-readable form and paper copy, formal drawings (3 sheets), and a Petition to Accept Color Photographs as Drawings, along with three color copies and one black & white copy of Figures 4A and 4B, and with the requisite petition fee.

The required statement concerning color drawings is already present in the specification, at page 8, lines 21-23, as the Examiner has acknowledged.

CONCLUSION

In view of the above amendments and remarks, it is submitted that this application is now ready for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney at (213) 896-6665.

Respectfully submitted,

By: 

Nisan A. Steinberg, Ph.D.

Reg. No. 40,345

SIDLEY AUSTIN BROWN & WOOD  
555 West Fifth Street, Suite 4000  
Los Angeles, California 90013  
Ofc: 213/ 896-6665  
Fax: 213/ 896-6600  
23066.1



**Version With Markings to Show Changes Made**

Deletions are indicated with bold brackets to distinguish them from brackets that are part of the desired text.

In the Specification:

Please delete the paragraph at page 4, lines 6-11, and insert therefor the following:

--Intracarotid infusion of leukotriene C<sub>[sub.4]</sub><sub>4</sub> (LTC<sub>4</sub>) selectively increases the permeability in brain tumor capillaries without affecting the permeability in normal brain capillaries. The effect of LTC<sub>4</sub> on brain tumor capillaries is, however, limited to small molecules and it can only slightly increase the permeability of those small molecules in abnormal brain tissue relative to normal. Accordingly, LTC<sub>4</sub> does not significantly increase the delivery of some larger water soluble molecules to brain tumors or other abnormalities.--.

Please delete the paragraph at page 11, lines 4-11, and insert therefor the following:

--However, the potassium channel agonist employed in the inventive methods is one other than the vasodilator bradykinin (Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg)(SEQ ID NO:1), or a polypeptide bradykinin analog, such as receptor mediated permeabilizer (RMP)-7 or A7 (e.g., Kozarich *et al.*, U.S. Patent No. 5,268,164 and PCT Application No. WO 92/18529). Other analogs of bradykinin include related peptide structures which exhibit the same properties as bradykinin but have modified amino acids or peptide extensions on either terminal end of the peptide. Examples of bradykinin analogs include [phe<sup>8</sup> (CH<sub>2</sub>-NH) Arg<sup>9</sup>-bradykinin, N-acetyl [phe<sup>8</sup> (CH<sub>2</sub>--NH--Arg<sup>9</sup>] bradykinin and desArg<sup>9</sup>-bradykinin.--.